TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05743621
Drug: TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol
Study: NCT05554939
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06791577
Drug: Carboxytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of the intervention (CO2 Lift) in the area according to the protocol schedule
Study: NCT06799845
Drug: ATX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX101 bupivacaine implants, total of 1,500 mg into the surgical site
Study: NCT06799845
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
Study: NCT05809908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose of IMP will be administered orally 30 minutes after completing a meal.~Subjects will titrate from 5 g twice a day to 20 g twice a day, 40 g total daily dose of safflower oil; 80 ml total daily dose of placebo, over the course of 3 weeks.
Study: NCT04760613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical capsules containing placebo (taken daily by mouth)
Study: NCT06785740
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use
Study: NCT06206564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
Study: NCT06785974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Placebo in combination with ICI-therapy
Study: NCT04699188
Drug: JDQ443
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS G12C inhibitor
Study: NCT05922878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule QD
Study: NCT06501443
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines
Study: NCT06501443
Drug: KJX839
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
Study: NCT06790862
Drug: SHR0302Base gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302Base gel.
Study: NCT06790862
Drug: SHR0302Base gel placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302Base gel placebo.
Study: NCT06627231
Drug: TEV-56286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06627231
Drug: [14C]-TEV-56286
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05150795
Drug: Fentanyl 100 micrograms ampoule
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compare the postoperative analgesic effect of pre-operative oral pregabalin (Study group), to the intraoperative intravenous fentanyl (Control group) in diagnostic laparoscopic gynecologic surgery.
Study: NCT06226545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously.
Study: NCT06226545
Drug: LASN01
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of LASN01 will be administered intravenously.
Study: NCT06566833
Drug: self assmbling peptide p11-4 combined with 0.05% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: biomimetic remineralizing agent
Study: NCT05099172
Drug: BAY2927088_formulation B_1
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05099172
Drug: BAY2927088_formulation B_2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06161519
Drug: PLX038
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX038 is given intravenously (IV) at the assigned dose level over about 1 hour on day 1 of each 21-day cycle
Study: NCT06799884
Drug: Ethinyl Estradiol / Levonorgestrel Oral Tablet
Normalized name: ethinyl estradiol / levonorgestrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated tablet of 20 µg ethinyl estradiol and 100 µg levonorgestrel
Study: NCT05479812
Drug: WTX-124
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigation Product Monotherapy
Study: NCT05178810
Drug: FAB122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose 100 mg
Study: NCT05178810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose
Study: NCT06253520
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study: NCT04935320
Drug: HTL0016878.HCl Solution 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution fasted
Study: NCT04935320
Drug: HTL0016878.Citrate Capsule 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule fed or fasted
Study: NCT05581030
Drug: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient.
Study: NCT05220514
Drug: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Study: NCT05847920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06539741
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study: NCT06539741
Drug: Acetaminophen 500mg
Normalized name: ACETAMINOPHEN 500MG CAP
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study: NCT04899115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting the last day of oral vancomycin (Day 1), subjects randomized to this arm will take 5 capsules of placebo for 14 days taken once daily.
Study: NCT06262919
Drug: Tafinlar/Mekinist
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05769660
Drug: BEY1107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer twice daily, PO, 4-week continuous dose.
Study: NCT06081894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06782932
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. 200 mg/m2 will be administered as a 30 minute IV infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 200 mg/m2 IV
Study: NCT06782932
Drug: AGEN2373 (RP2D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Drug: Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be administered as a 60 minute IV. Infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV
Study: NCT06782932
Drug: mKRASvax
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. mKRASvax will be administered on Day 1 of each cycle and on Day 8 of Cycle 1 only. mKRASvax is given as 5 subcutaneous injections administered in the upper thighs and arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC
Study: NCT06332599
Drug: PBM4M4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
Study: NCT06332599
Drug: PBM3M3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
Study: NCT06332599
Drug: PBM2M4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
Study: NCT06332599
Drug: PBM2M3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
Study: NCT05632159
Drug: conventional anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.
Study: NCT05026593
Drug: IBI110
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
Study: NCT04823611
Drug: Part A:Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT04823611
Drug: Part A:AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study: NCT04823611
Drug: Part B:Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT04823611
Drug: Part B:AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study: NCT04823611
Drug: Part C: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT04823611
Drug: Part C: AZD8233
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study: NCT04927195
Drug: EDP1867
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Study: NCT04927195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT05417646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator to empagliflozin
Study: NCT05704361
Drug: RO7121932 - MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 3: Participants will receive multiple doses of RO7121932 administered as SC injections.
Study: NCT05809934
Drug: AZD2693
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2693 solution SC once per month
Study: NCT04827953
Drug: NLM-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLM-001 will be administered three cycles consecutively followed by two rest cycles.
Study: NCT06789796
Drug: QL1604
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, every 3 weeks
Study: NCT06789796
Drug: placebo for Iparomlimab and Tuvonralimab (QL1706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 3 weeks
Study: NCT06736288
Drug: BUCCALIN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant tablets (mixture of Streptococcus pneumoniae I, II, III, Streptococcus agalactiae, Staphylococcus aureus, Haemophilus influenzae).~The recommended dosage is 1 tablet on day 1, 2 tablets on day 2, and 4 tablets on day 3 and should be taken in the morning on an empty stomach.
Study: NCT06628908
Drug: Placebo (matched to SUZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to SUZ for oral administration.
Study: NCT06628908
Drug: Placebo (matched to Pregabalin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to Pregabalin for oral administration.
Study: NCT06100887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally once per day
Study: NCT06248593
Drug: Continuous infusion of Norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
Study: NCT04771156
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
Study: NCT04771156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
Study: NCT04745299
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cycle administration group: Placebo comparator is injected three times every three months after injection of Lenzumestrocel twice in a 26-day interval.~Control group: Placebo comparator is injected twice in a 26-day interval followed by repeated three times injcections every three months
Study: NCT05750966
Drug: cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (24 hours)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The duration of antibiotics is 24 hours after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
Study: NCT05750966
Drug: cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline (4 to 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The duration of antibiotics is 4 to 7 days after adequate biliary drainage. The choice of antibiotics will be according to local protocol and/or national Dutch SWAB guidelines. The most common antibiotics are described above, but this can differ based on allergies, local protocol or previous cultures. Drug classes may include: aminoglycosides, carbapenems, cefalosporins, fluorquinolones, sulfonamides, penicillines.
Study: NCT06101784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cohort 6 subjects will be assigned to the active treatment and 2 subjects will be assigned to the placebo.
Study: NCT05889156
Drug: NST-1024
Normalized name: GLOVE NITRILE SM PFREE NSTERL TX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BID
Study: NCT06158126
Drug: Initiating daily oral PrEP during pregnancy
Normalized name: Daily Hist Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1a will include pregnant women who initiate oral PrEP when already pregnant, at enrollment into the study.
Study: NCT05722860
Drug: L-Citrulline, capsule
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5g/daily dose for the duration of 1 week intervention
Study: NCT06301997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice daily for 3 weeks after enrolment
Study: NCT06411899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06772441
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant
Study: NCT05138757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.
Study: NCT06444529
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle
Study: NCT05707897
Drug: TS-142 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of 10 mg of TS-142
Study: NCT05842174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2
Study: NCT04474847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week. Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 3 will have the option of entering an open-label trial period whereby they would receive open-label abatacept for up to 12 months.
Study: NCT04795856
Drug: [11C] acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Tracer
Study: NCT04963296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
Study: NCT04963296
Drug: Acetaminophen/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study: NCT05717621
Drug: VTD-101 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of VTD-101 ointment (Decitabine ointment)
Study: NCT00002276
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05561725
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will receive one 8mg dose of dexamethasone intraoperatively as per standard of care anesthesia protocols. No sham medication will be utilized for control subjects.~All patients will undergo a standardized post-operative pathway in the hospital following surgery that has been utilized for all AIS patients at our center since 2014.
Study: NCT05438329
Drug: DB-1305/BNT325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Injection of Vein (I.V.)
Study: NCT05438329
Drug: BNT327
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered I.V.
Study: NCT06792812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
Study: NCT06563804
Drug: S227928
Approvals — FDA: no, EMA: no, PMDA: no
Description: For administration via intravenous (IV) infusion
Study: NCT04053842
Drug: [18F]PSMA-1007 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]PSMA-1007 is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
Study: NCT06794996
Drug: Inaxaplin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for Oral Administration.
Study: NCT06797024
Drug: JY231 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.
Study: NCT05358938
Drug: Checkpoint Blockade, Immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
Study: NCT06794710
Drug: diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive pharmacological treatment for heart failure.
Study: NCT05548426
Drug: Group A, Penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Study: NCT05930938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xevinapant without active substance
Study: NCT06794385
Drug: dinoprostone vaginal delivery system
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women in this group will receive a vaginal delivery system containing 10 mg of dinoprostone for labor induction.
Study: NCT05107336
Drug: AZD2693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injection of AZD2693, once per month.
Study: NCT05107336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.